RT Journal Article
SR Electronic
T1 <em>In silico</em> cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.09.21263319
DO 10.1101/2021.09.09.21263319
A1 Creemers, Jeroen H.A.
A1 Roes, Kit C.B.
A1 Mehra, Niven
A1 Figdor, Carl G.
A1 de Vries, I. Jolanda M.
A1 Textor, Johannes
YR 2021
UL http://medrxiv.org/content/early/2021/09/13/2021.09.09.21263319.abstract
AB Background Late-stage cancer immunotherapy trials strive to demonstrate the clinical efficacy of novel immunotherapies, which is leading to exceptional responses and long-term survival in subsets of patients. To establish the clinical efficacy of an immunotherapy, it is critical to adjust the trial’s design to the expected immunotherapy-specific response patterns.Methods In silico cancer immunotherapy trials are virtual clinical trials that simulate the kinetics and outcome of immunotherapy depending on the type and treatment schedule. We used an ordinary differential equation model to simulate (1) cellular interactions within the tumor microenvironment, (2) translates these into disease courses in patients, and (3) assemble populations of virtual patients to simulate in silico late-stage immunotherapy, chemotherapy, or combination trials. We predict trial outcomes and investigate how therapy-specific response patterns affect the probability of their success.Results In silico cancer immunotherapy trials reveal that immunotherapy-derived survival kinetics – such as delayed curve separation and plateauing curve of the treatment arm – arise naturally due to biological interactions in the tumor microenvironment. In silico clinical trials are capable of translating these biological interactions into survival kinetics. Considering four aspects of clinical trial design – sample size calculations, endpoint and randomization rate selection, and interim analysis planning – we illustrate that failing to consider such distinctive response patterns can significantly reduce the power of novel immunotherapy trials.Conclusion In silico trials have three significant implications for immuno-oncology. First, they provide an economical approach to verify the robustness of biological assumptions underlying an immunotherapy trial and help to scrutinize its design. Second, the biological basis of these trials facilitates and encourages communication between biomedical researchers, doctors, and trialists. Third, its application as an educational tool can illustrate design principles to scientists in training, contributing to improved designs and higher success rates of future immunotherapy trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJC was funded by the Radboudumc. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant. IV received an NWO-Vici grant (918.14.655). JT was supported by a Young Investigator Grant (10620) from the Dutch Cancer Society and an NWO grant (VI.Vidi.192.084).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code is available at GitHub: https://github.com/jeroencreemers/in-silico-clinical-trials https://github.com/jeroencreemers/in-silico-clinical-trials ICIimmune checkpoint inhibitorNCCTGNorth Central Cancer Treatment GroupODEordinary differential equationOSoverall survivalPHAproportional hazard assumption